Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
BCAX Stock Chart & Stats
$16.75
-$0.31(-1.97%)
At close: 4:00 PM EST
$16.75
-$0.31(-1.97%)
Day’s Range― - ―
52-Week Range$7.80 - $19.71
Previous CloseN/A
Volume80.52K
Average Volume (3M)560.48K
Market Cap
$917.60M
Enterprise Value$573.37M
Total Cash (Recent Filing)$290.17M
Total Debt (Recent Filing)$1.98M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Mar 26, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding54,781,950
10 Day Avg. Volume498,219
30 Day Avg. Volume560,478
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)1.93
Price to Sales (P/S)0.00
P/FCF Ratio-12.67
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.20
Forecast
1Y Price Target
$30.78Price Target Upside83.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Dose SelectionFDA-aligned selection of a higher Phase 3 dose based on stronger complete responses with a comparable safety profile supports a robust pivotal study design.
FundingAvailable cash fully funds the pivotal trial through the confirmatory endpoint, reducing the need for near-term financing and lowering dilution risk.
Pipeline ExpansionPlanned colorectal cancer data and inclusion of metastatic colorectal cancer as a target indication could validate multi-indication potential and meaningfully expand the addressable market if responses are strong.
Bears Say
CompetitionA crowded bispecific therapy field with multiple competitors showing strong responses increases the risk that the drug will struggle to achieve best-in-class status and capture market share.
Development Timeline RiskClinical setbacks, delays, or being behind a competitor on topline readout could narrow the opportunity to secure a first-to-market advantage and amplify downside risk.
Safety And TolerabilityConcerns that the TGFβ component may add little efficacy while heightening safety risks, including anemia, bleeding, and cardiovascular events, could impair treatment persistence and regulatory outcomes.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $7.80 and its highest was $19.71 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $917.60M.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 66 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Nov 18, 2025. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.541 by -$0.129.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -0.68.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 54,781,950 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.541. Following the earnings report the stock price went up 3.455%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicara Therapeutics Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.78 (83.76% Upside)
$30.78 (83.76% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.99%
12-Months-Change
Fundamentals
Return on Equity
-26.64%
Trailing 12-Months
Asset Growth
-18.98%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
BCAX Stock 12 Month Forecast
Average Price Target
$30.78
▲(83.76% Upside)
Technical Analysis
Arbutus Biopharma
―
Bicycle Therapeutics
―
Relay Therapeutics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
17.68% Insiders
11.13% Mutual Funds
<0.01% Other Institutional Investors
61.94% Public Companies and
Individual Investors